Renal Cell Carcinoma Clinical Roundup
(City of Hope) Aug 19, 2020 - Greater gut microbial diversity in patients with metastatic kidney cancer is associated with better treatment outcomes on FDA-approved immunotherapy regimens, based on a study published today in the journal European Urology.
(Yahoo! News) Aug 18, 2020 - Arrowhead Pharmaceuticals Inc. today announced that it has dosed the first patient in AROHIF21001, a Phase 1b dose-finding clinical study of ARO-HIF2, the company’s investigational RNA interference (RNAi) therapeutic being developed as a treatment for patients with clear cell renal cell carcinoma (ccRCC).
(Yahoo! Finance) Aug 18, 2020 - Median Overall Survival (OS) was reached at 25 months in the control group treated with sunitinib, while the final median OS value in the ilixadencel treatment group has not yet been reached, indicating a survival benefit in the study’s co-primary endpoint.
(Medscape Medical News) Aug 13, 2020 - Postmenopausal women with BMIs under 30 are paradoxically more likely to develop kidney cancer than the women of the same age with higher BMIs and larger waists.
(Clinical cancer research : an official journal of the American Association for Cancer Research) - 2020-08-21
(International journal of cancer) - 2020-08-02
(Clinical cancer research : an official journal of the American Association for Cancer Research) - 2020-08-01
At the ASCO20 Virtual Education Program, Jaleh Fallah, MD, a Hematology/Oncology Fellow at the Cleveland Clinic, reviewed the outcomes of single-agent immunotherapy and immunotherapy-based combinations in the front-line renal cell carcinoma setting and discussed the choice of treatment following disease progression.